6th Annual Cell Engager Summit

The 6th Annual Cell Engager Summit covers topics such as:

• A Novel Class of NK-cell Engagers for Tumor Targeting
• Analyzing Target Selection to Maximize Efficacy Whilst Minimizing Toxicity
• Humabody® VH as T-cell Enhancing Therapeutics for Immuno Oncology
• The ImmTACTM Platform: Progress and Clinical Insight from the Soluble TCR-based Bispecific Approach
• Reducing Key Toxicities with T Cell Engaging Bispecifics
• The Promise of Next Generation T Cell Engagers for Cancer Treatment
• Omid Vafa
• A Novel Multispecific T Cell Engager Platform for a Better Therapeutic Window
• Rational Combinations for Bispecific T-cell Engager (BiTE®) Immune Therapy in Solid Tumors
• Prevention and Treatment of CRS with Bispecific Antibodies
• Mechanisms of Bispecific T cell Engager Efficacy and Toxicity in Murine Tumor Models
• Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs